Treatment of Achalasia by Injection of Sclerosant Substances: A Long-Term Report
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Endoscopic sclerotherapy (EST) with ethanolamine oleate (EO) was proposed as a treatment for achalasia, based on the well-known necrotizing effect against the esophageal muscle layers. The aim of this study is to evaluate long-term efficacy of EST.
Four consecutive series of patients with achalasia were treated according to different schedules over a period of 20 years, by using EO or polidocanol (PD). The primary outcome was dysphagia relief. Secondary outcomes were lower esophageal sphincter pressure, esophagogram, gastroesophageal reflux and endoscopic ultrasonography (EUS). Patients not responding to EST were treated with 30 mm dilation.
A total of 103 patients completed the treatment. On medium-term evaluation, 75 patients who completed the treatment reached a clinical response labeled as “good,” 23 were assessed as “fair,” and 5 were assessed as failures. EUS has become a very informative tool to guide the treatment. The overall follow-up lasted for 87.9 ± 66.7 months. Twelve patients experienced a late failure. The cumulative expectancy of being free of recurrence was 90 % at 50 months with EO, but it was only 65 % with PD. Those patients who responded to rescue measures remained in good or fair clinical condition during the remaining follow-up. Young age, PD, and the so-called fusiform pattern on esophagogram proved to be significant predictors of poor prognosis.
EST with EO is a promising alternative to classic therapies for achalasia. In contrast, PD-treated patients showed an important trend to fibrosis and clinical recurrence. Dilation seems particularly effective after EST, when this technique has failed.
- Evans DMD, Jones DB, Cleary BK, et al. Oesophageal varices treated by sclerotherapy: a histopathological study. Gut. 1982;23:615–620. CrossRef
- Papadimos D, Kerlin P, Harris OD. Endoscopic sclerotherapy: lessons from a necropsy study. Gastrointest Endosc. 1986;32:269–273. CrossRef
- Kitano S, Wada H, Tanoue K, et al. Comparative effects of 5% ethanolamine oleate versus 5% ethanolamine oleate plus polidocanol for sclerosing esophageal varices. Hepatogastroenterology. 1992;39:546–548.
- Ogle SJ, Kirk CJC, Bailey RJ, et al. Oesophageal function in cirrhotic patients undergoing injection sclerotherapy for oesophageal varices. Digestion. 1978;18:178–185. CrossRef
- Sharma P, Hagerstrand I, Sharma DK. Histologic and manometric studies on the esophagus following endoscopic sclerotherapy. Dig Dis Sci. 2009;54:1713–1719. CrossRef
- Kinoshita Y, Kitajima N, Itoh T, et al. Gastroesophageal Reflux alter endoscopic injection sclerotherapy. Am J Gastroenterol. 1992;87:282–286.
- Moretó M, Ojembarrena E, Rodríguez ML. Endoscopic ethanolamine as a treatment for achalasia: a first report. Endoscopy. 1996;28:539–545. CrossRef
- DeMeester TR, Wang CL, Wernly JA, et al. Technique, indications, and clinical use of 24 hour esophageal pH monitoring. J Thorac Cardiovasc Surg. 1980;79:656–670.
- Boeckxstaens G, Annese V, Bruley des Varannes S, et al. Pneumatic dilation versus laparoscopic Heller’s myotomy for idiopathic achalasia. N Engl J Med. 2011;364:1807–1816. CrossRef
- Papo M, Mearin F, Castro JR, et al. Chest pain reappearance oesophageal peristalsis in treated achalasia. Scand J Gastroenterol. 1997;32:1190–1194. CrossRef
- Niknam R, Mikaeli J, Mehrabi N, et al. Ethanolamine oleate in resistant idiopathic achalasia: a novel therapy. Eur J Gastroenterol Hepatol. 2011;23:1111–1115. CrossRef
- Cauncedo A, Romero R, Hergueta P, et al. Estudio de la eficacia de tres modalidades de terapia endoscópica en la acalasia. Rev Esp Enferm Dig. 2003;94:13–21.
- Rohof WO, Hirsch DP, Kessing BF, et al. Efficacy of treatment for patients with achalasia depends on the distensibility of the esophagogastric junction. Gastroenterology. 2012;143:328–335. CrossRef
- Nishida R, Inoue R, Takimoto Y, et al. Endoscopic sclerotherapy in a rat modelo f esophageal varices. Scand J Gastroenterol. 1995;30:489–496. CrossRef
- Eckart VK, Kanzier G, Werstermeir T. Complications and their impact after pneumatic dilation for achalasia: prospective long-term study. Gastrointest Endosc. 1997; 45:349–353.
- Ponce J, Garrigues V, Pertejo V, et al. Individual prediction of response to pneumatic dilation in patients with achalasia. Dig Dis Sci. 1996;41:2135–2141. CrossRef
- Alderliesten J, Conchillo JM, Leeuwenburgh I, et al. Predictors for outcome of failure of balloon dilatation in patients with achalasia. Gut. 2011;60:10–16. CrossRef
- Eckart VF, Aignherr C, Bernhard G. Predictors of outcome in patients with achalasia treated by pneumatic dilation. Gastroenterology. 1992;103:1732–1738.
- Vaezi MF, Baker ME, Achkar E, et al. Timed barium oesophagogram: better predictor of long term success after pneumatic dilation in achalasia than symptom assessment. Gut. 2002;50:765–770. CrossRef
- Chuah SK, Hu TH, Wu KL, et al. The role of barium esophagogram measurements in assessing achalasia patients after endoscope-guided pneumatic dilation. Dis Esophagus. 2009;22:163–168. CrossRef
- Pandolfino JE, Kwiatek MA, Nealis T, et al. Achalasia: a new clinically relevant classification by high-resolution manometry. Gastroenterology. 2008;135:1526–1533. CrossRef
- Kinoshita Y, Kitajima N, Itoh T, et al. Gastroesophageal reflux after endoscopic injection sclerotherapy. Am J Gastroenterol. 1992;87:282–286.
- Treatment of Achalasia by Injection of Sclerosant Substances: A Long-Term Report
Digestive Diseases and Sciences
Volume 58, Issue 3 , pp 788-796
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Esophageal achalasia
- Industry Sectors
- Author Affiliations
- 1. Gastroenterology and Hepatology Unit, Hospital de Cruces, Medical School, University of the Basque Country, Plaza de Cruces s/n, 48903, Barakaldo, Basque Country, Spain
- 2. Av. Zugazarte, 56, V, 4-B, 48930, Getxo, Spain